Molecular Cell Therapy, Center for Biotechnology and Biomedicine (BBZ), Universität Leipzig, Leipzig, Germany.
PLoS One. 2013 Sep 3;8(9):e73207. doi: 10.1371/journal.pone.0073207. eCollection 2013.
Mitochondria are involved in a variety of cellular biochemical pathways among which the ATP production by oxidative phosphorylation (OXPHOS) represents the most important function of the organelle. Since mitochondria contain their own genome encoding subunits of the OXPHOS apparatus, mtDNA mutations can cause different mitochondrial diseases. The impact of these mutations can be characterized by the trans-mitochondrial cybrid technique based on mtDNA-depleted cells (ρ(0)) as acceptors of exogenous mitochondria. The aim of the present work was to compare ρ(0) cells obtained by long term ethidium bromide treatment and by a mitochondrial targeted restriction endonuclease, respectively, as mitochondrial acceptors for trans-mitochondrial cybrid generation. Fusion cells have mitochondrial respiratory functions comparable to their parental wild type cells, regardless the strategy utilized to obtain the ρ(0) acceptor cells. Therefore, the newly developed enzymatic strategy for mtDNA depletion is a more convenient and suitable tool for a broader range of applications.
线粒体参与多种细胞生化途径,其中通过氧化磷酸化(OXPHOS)产生的 ATP 是细胞器最重要的功能之一。由于线粒体含有自己的基因组,编码 OXPHOS 装置的亚基,因此 mtDNA 突变会导致不同的线粒体疾病。这些突变的影响可以通过基于 mtDNA 耗竭细胞(ρ(0))作为外源线粒体接受体的转线粒体细胞杂交技术来表征。本工作的目的是比较分别通过长期溴化乙锭处理和靶向线粒体的限制性内切酶获得的 ρ(0)细胞,作为转线粒体细胞杂交生成的线粒体接受体。融合细胞具有与亲本野生型细胞相当的线粒体呼吸功能,无论用于获得 ρ(0)接受细胞的策略如何。因此,新开发的用于 mtDNA 耗竭的酶切策略是一种更方便、更适合更广泛应用的工具。